[1] Kornblihtt AR, Pesce CG, Srebrow A, et al. The fibronectin gene as a model for splicing and transcription studies [J]. FASEB J,1996,10∶248-257
[2] Satish L, Gallo PH, Kathju S, et al. Reversal of TGF-beta1 stimulation of alpha-smooth muscle actin and extracellular matrix components by cyclic AMP in Dupuytren's-derived fibroblasts [J]. BMC Musculoskelet Disord,2011,12∶113
[3] Medina-Ortiz WE, Belmares R, Clark AF, et al. Cellular fibronectin expression in human trabecular meshwork and induction by transforming growth factor-beta2 [J]. Invest Ophthalmol Vis Sci,2013,54∶6779-6788
[4] White ES, Sagana RL, Cornett AM, et al. Control of fibroblast fibronectin expression and alternative splicing via the PI3K/Akt/mTOR pathway [J]. Experimental Cell Research,2010,316∶2644-2653
[5] McFadden JP, Baker BS, Fry L, et al. Psoriasis and extra domain A fibronectin loops [J]. Br J Dermatol,2010,163∶5-11
[6] Ou J, Li J, Zhou Q, et al. Endostatin suppresses colorectal tumor-induced lymphangiogenesis by inhibiting expression of fibronectin extra domain A and integrin alpha9 [J]. J Cell Biochem,2011,112∶2106-2114
[7] Shinde AV, Kelsh R, Van De Water L, et al. The α4β1 integrin and the EDA domain of fibronectin regulate a profibrotic phenotype in dermal fibroblasts [J]. Matrix Biology,2014
[8] Kohan M, Muro AF, White ES, et al. EDA-containing cellular fibronectin induces fibroblast differentiation through binding to alpha4beta7 integrin receptor and MAPK/Erk 1/2-dependent signaling [J]. FASEB J,2010,24∶4503-4512
[9] Arribillaga L, Durantez M, Rehberger F, et al. A fusion protein between streptavidin and the endogenous TLR4 ligand EDA targets biotinylated antigens to dendritic cells and induces T cell responses in vivo [J]. Biomed Res Int, 2013∶864720
[10] Warawdekar UM, Jagannath P, Mehta AR, et al. Elevated levels and fragmented nature of cellular fibronectin in the plasma of gastrointestinal and head and neck cancer patients [J]. Clin Chim Acta, 2006, 372∶83-93
[11] Schwager K, Villa A, Neri D, et al. A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer [J]. Head Neck Oncol,2011, 3∶25
[12] Ou J, Deng J, Wei X, et al. Fibronectin extra domain A (EDA) sustains CD133(+)/CD44(+) subpopulation of colorectal cancer cells [J]. Stem Cell Res, 2013, 11∶820-833
[13] Ou J, Peng Y, Deng J, et al. Endothelial cell-derived fibronectin extra domain A promotes colorectal cancer metastasis via inducing epithelial-mesenchymal transition [J]. Carcinogenesis, 2014, 35∶1661-1670
[14] Ou J, Pan F, Geng P, et al. Silencing fibronectin extra domain A enhances radiosensitivity in nasopharyngeal carcinomas involving an FAK/Akt/JNK pathway [J]. Int J Radiat Oncol Biol Phys, 2012, 82∶e685-691
[15] Arribillaga L, Dotor J, Basagoiti M, et al. Therapeutic effect of a peptide inhibitor of TGF-beta on pulmonary fibrosis [J]. Cytokine, 2011, 53∶327-333
[16] Babaev VR, Porro F, Baralle FE, et al. Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice [J]. Atherosclerosis, 2008, 197∶534-540
[17] Booth AJ, Wood SC, Lu G, et al. Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis [J]. J Pathol, 2012, 226∶609-618
[18] Rudilla F, Fayolle C, Arribillaga L, et al. Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses. Vaccine, 2012, 30∶2848-2858
[19] McFadden JP, Basketter DA, Kimber IR, et al. Extra domain A-positive fibronectin-positive feedback loops and their association with cutaneous inflammatory disease [J]. Clin Dermatol, 2011, 29∶257-265
[20] Losino N, Waisman A, Espinosa DF, et al. EDA-containing fibronectin increases proliferation of embryonic stem cells [J]. PLoS One, 2013, 8∶e80681
[21] Mansilla C, Berraondo P, Casares N, et al. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin [J]. Int J Cancer,2012,131∶641-651
[22] Frey K, Zivanovic A, Neri D, et al. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation [J]. Integrative Biolog,2011,3∶468
[23] Moschetta M, Pretto F, Richter P, et al. Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectin-Positive Metastatic Human Melanoma Xenografts [J]. Cancer Research,2012,72∶1814-1824
[24] Hackl NJ, Bersch C, Franke A, et al. Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C [J]. Scandinavian Journal of Gastroenterology,2010, 45∶349-356
[25] Peters JH, Grote MN, Maunder RJ , et al. Changes in plasma fibronectin isoform levels predict distinct clinical outcomes in critically ill patients [J]. Biomark Insights,2011,6∶59-68 |
